Brokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $115.92

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been given an average recommendation of “Hold” by the twenty ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $115.92.

A number of analysts have commented on the company. Mizuho lifted their target price on Neurocrine Biosciences from $99.00 to $103.00 and gave the stock a “neutral” rating in a report on Tuesday, November 2nd. BMO Capital Markets assumed coverage on Neurocrine Biosciences in a report on Thursday, November 18th. They issued an “underperform” rating and a $76.00 price objective for the company. Needham & Company LLC assumed coverage on Neurocrine Biosciences in a report on Wednesday, September 22nd. They issued a “hold” rating for the company. Raymond James cut their price objective on Neurocrine Biosciences from $163.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, November 2nd. Finally, Royal Bank of Canada cut their price objective on Neurocrine Biosciences from $130.00 to $119.00 and set an “outperform” rating for the company in a report on Tuesday, November 2nd.

In other news, Director Gary A. Lyons sold 5,000 shares of the business’s stock in a transaction dated Thursday, October 7th. The stock was sold at an average price of $105.06, for a total value of $525,300.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Dimitri E. Grigoriadis sold 8,000 shares of the business’s stock in a transaction dated Thursday, October 7th. The shares were sold at an average price of $104.81, for a total value of $838,480.00. The disclosure for this sale can be found here. Insiders have sold 13,987 shares of company stock worth $1,464,188 over the last quarter. 4.30% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the stock. CI Investments Inc. purchased a new stake in shares of Neurocrine Biosciences in the third quarter worth about $39,000. Berman Capital Advisors LLC increased its stake in Neurocrine Biosciences by 139.0% during the second quarter. Berman Capital Advisors LLC now owns 411 shares of the company’s stock worth $39,000 after acquiring an additional 239 shares during the last quarter. KB Financial Partners LLC bought a new stake in Neurocrine Biosciences during the first quarter worth approximately $43,000. Meeder Asset Management Inc. increased its stake in Neurocrine Biosciences by 460.0% during the third quarter. Meeder Asset Management Inc. now owns 504 shares of the company’s stock worth $48,000 after acquiring an additional 414 shares during the last quarter. Finally, Private Capital Group LLC increased its stake in Neurocrine Biosciences by 98.4% during the third quarter. Private Capital Group LLC now owns 603 shares of the company’s stock worth $58,000 after acquiring an additional 299 shares during the last quarter. Institutional investors own 95.30% of the company’s stock.

Neurocrine Biosciences stock opened at $87.86 on Monday. The firm has a market cap of $8.34 billion, a price-to-earnings ratio of 19.23 and a beta of 0.70. The stock has a fifty day simple moving average of $96.93 and a two-hundred day simple moving average of $95.87. Neurocrine Biosciences has a 12 month low of $84.50 and a 12 month high of $120.27. The company has a current ratio of 4.45, a quick ratio of 4.34 and a debt-to-equity ratio of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, November 1st. The company reported $0.23 EPS for the quarter, missing the Zacks’ consensus estimate of $0.51 by ($0.28). The business had revenue of $296.00 million during the quarter, compared to the consensus estimate of $297.02 million. Neurocrine Biosciences had a return on equity of 35.89% and a net margin of 41.59%. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.62) EPS. On average, equities research analysts forecast that Neurocrine Biosciences will post 1.6 EPS for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm’s product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W.

Recommended Story: What is channel trading?

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.